Muthiah Vaduganathan
Muthiah Vaduganathan is an expert in Cardiology at Brigham and Women's Hospital (United States). As of October 2026, ScienceLeadR ranks Muthiah Vaduganathan in the top 1% of experts worldwide for Heart Failure, Diabetes Mellitus and Glucose Metabolism Disorders. Muthiah Vaduganathan has authored 1,223 publications, the most recent in 2026, and is an investigator in 37 clinical trials, 4 of them ongoing. SLR score: 5,920 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Endocrinology - Nephrology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2008 - 2026
Number : 1223
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study. PMID 41904995 — heart failure, health status, prealbumin, amyloidosis, therapeutics, cardiomyopathies, transthyretin amyloidosis | Eur J Heart Fail | 2026 | 0 |
| Redefining Cardiometabolic Disease: Expert Consensus on the CardioVascular-Kidney-Liver-Metabolic (CVKLM) Multiorgan Staging. PMID 42945405 — liver diseases, diabetes mellitus, heart, cardiovascular diseases, kidney, liver, obesity, therapeutics | Eur J Prev Cardiol | 2026 | 0 |
| Prevalence and clinical correlates of metabolic dysfunction-associated steatotic liver disease in heart failure. PMID 42906951 — liver diseases, heart failure, heart, cardiovascular diseases, liver, prevalence | Open Heart | 2026 | 0 |
| Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium. PMID 42675244 — blood, serum, heart failure, molecular biology, heart, blood pressure, heart failure, diastolic, kidney, heart failure, systolic, therapeutics | Nat Med Top journal | 2026 | 0 |
| Toward Targeted Population-Level Screening for Heart Failure. PMID 42872756 — diabetes mellitus, heart failure, heart, cardiology, natriuretic peptides | J Am Coll Cardiol | 2026 | 0 |
Clinical Studies 37
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Adherence to Dyslipidemia Therapy Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease NCT07522645 — diabetes mellitus, electronic mail, spermine, patient portals, communication, cardiovascular diseases, dyslipidemias, prescriptions, therapeutics, spermine synthase, hydroxymethylglutaryl-coa reductase inhibitors, environment, non-responder | N/A | Active not recruiting | 2026 |
| Kaiser Permanente VACCination Improvement With Nudge based CardiovAscular Targeted Engagement NCT06571747 — myocardial infarction, vaccines, social behavior, heart failure, heart, communication, cardiovascular diseases, vaccination, behavioral sciences, influenza, human, implementation science | N/A | Active not recruiting | 2024 |
| Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD NCT05359263 — kidney diseases, double-blind method, kidney, renal insufficiency, renal insufficiency, chronic | Phase 2 | Recruiting | 2022 |
| Flow Regulation by Opening the SepTum in Patients With Heart Failure a Prospective Randomized Sham controlled Double blind Global Multicenter Study NCT05136820 — heart failure, heart, heart failure, diastolic, heart failure, systolic, therapeutics | N/A | Active not recruiting | 2023 |
LeadR Networks
Main global connection map